Inflammatory biomarkers in Alzheimer's disease plasma

Morgan, A.R.; Touchard, S.; Leckey, C.; O'Hagan, C.; Nevado-Holgado, A.J.; Barkhof, F.; Bertram, L.; Blin, O.; Bos, I.; Dobricic, V.; Engelborghs, S.; Frisoni, G.; Frolich, L.; Gabel, S.; Johannsen, P.; Kettunen, P.; Kloszewska, I.; Legido-Quigley, C.; Lleo, A.; Martinez-Lage, P.; Mecocci, P.; Meersmans, K.; Molinuevo, J.L.; Peyratout, G.; Popp, J.; Richardson, J.; Sala, I.; Scheltens, P.; Streffer, J.; Soininen, H.; Tainta-Cuezva, M.; Teunissen, C.; Tsolaki, M.; Vandenberghe, R.; Visser, P.J.; Vos, S.; Wahlund, L.-.; Wallin, A.; Westwood, S.; Zetterberg, H.; Lovestone, S.; Morgan, B.P.; Bullmore, E.T.; Bhatti, J.; Chamberlain, S.J.; Correia, M.M.; Crofts, A.L.; Dickinson, A.; Foster, A.C.; Kitzbichler, M.G.; Knight, C.; Lynall, M.-.; Maurice, C.; O'Donnell, C.; Pointon, L.J.; St George Hyslop, P.; Turner, L.; Vertes, P.; Widmer, B.; Williams, G.B.; Leckey, C.A.; Cavanagh, J.; Deith, C.; Farmer, S.; Mcclean, J.; Mccoll, A.; Mcpherson, A.; Scouller, P.; Sutherland, M.; Boddeke, H.W.G.M.; Richardson, J.C.; Khan, S.; Murphy, P.; Parker, C.A.; Patel, J.; Jones, D.; de Boer, P.; Kemp, J.; Drevets, W.C.; Nye, J.S.; Wittenberg, G.; Isaac, J.; Bhattacharya, A.; Carruthers, N.; Kolb, H.; Pariante, C.M.; Turkheimer, F.; Barker, G.J.; Byrom, H.; Cash, D.; Cattaneo, A.; Gee, A.; Hastings, C.; Mariani, N.; Mclaughlin, A.; Mondelli, V.; Nettis, M.; Nikkheslat, N.; Randall, K.; Sheridan, H.; Simmons, C.; Singh, N.; Van Loo, V.; Vicente-Rodriguez, M.; Wood, T.C.; Worrell, C.; Zajkowska, Z.; Plath, N.; Egebjerg, J.; Eriksson, H.; Gastambide, F.; Adams, K.H.; Jeggo, R.; Thomsen, C.; Pederson, J.T.; Campbell, B.; Moller, T.; Nelson, B.; Zorn, S.; O'Connor, J.; Attenburrow, M.J.; Baird, A.; Benjamin, J.; Clare, S.; Cowen, P.; Huang, I.-.D.; Hurley, S.; Jones, H.; Mada, F.; Nevado-Holgado, A.; Oladejo, A.; Ribe, E.; Smith, K.; Vyas, A.; Hughes, Z.; Balice-Gordon, R.; Duerr, J.; Piro, J.R.; Sporn, J.; Perry, V.H.; Cleal, M.; Fryatt, G.; Gomez-Nicola, D.; Mancuso, R.; Reynolds, R.; Harrison, N.A.; Cercignani, M.; Clarke, C.L.; Hoskins, E.; Kohn, C.; Murray, R.; Wilcock, L.; Wlazly, D.; Mount, H.

doi:10.1016/j.jalz.2019.03.007

Introduction: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Inflammatory biomarkers in Alzheimer's disease plasma / A.R. Morgan, S. Touchard, C. Leckey, C. O'Hagan, A.J. Nevado-Holgado, F. Barkhof, L. Bertram, O. Blin, I. Bos, V. Dobricic, S. Engelborghs, G. Frisoni, L. Frolich, S. Gabel, P. Johannsen, P. Kettunen, I. Kloszewska, C. Legido-Quigley, A. Lleo, P. Martinez-Lage, P. Mecocci, K. Meersmans, J.L. Molinuevo, G. Peyratout, J. Popp, J. Richardson, I. Sala, P. Scheltens, J. Streffer, H. Soininen, M. Tainta-Cuezva, C. Teunissen, M. Tsolaki, R. Vandenberghe, P.J. Visser, S. Vos, L.-. Wahlund, A. Wallin, S. Westwood, H. Zetterberg, S. Lovestone, B.P. Morgan, E.T. Bullmore, J. Bhatti, S.J. Chamberlain, M.M. Correia, A.L. Crofts, A. Dickinson, A.C. Foster, M.G. Kitzbichler, C. Knight, M.-. Lynall, C. Maurice, C. O'Donnell, L.J. Pointon, P. St George Hyslop, L. Turner, P. Vertes, B. Widmer, G.B. Williams, C.A. Leckey, J. Cavanagh, C. Deith, S. Farmer, J. Mcclean, A. Mccoll, A. Mcpherson, P. Scouller, M. Sutherland, H.W.G.M. Boddeke, J.C. Richardson, S. Khan, P. Murphy, C.A. Parker, J. Patel, D. Jones, P. de Boer, J. Kemp, W.C. Drevets, J.S. Nye, G. Wittenberg, J. Isaac, A. Bhattacharya, N. Carruthers, H. Kolb, C.M. Pariante, F. Turkheimer, G.J. Barker, H. Byrom, D. Cash, A. Cattaneo, A. Gee, C. Hastings, N. Mariani, A. Mclaughlin, V. Mondelli, M. Nettis, N. Nikkheslat, K. Randall, H. Sheridan, C. Simmons, N. Singh, V. Van Loo, M. Vicente-Rodriguez, T.C. Wood, C. Worrell, Z. Zajkowska, N. Plath, J. Egebjerg, H. Eriksson, F. Gastambide, K.H. Adams, R. Jeggo, C. Thomsen, J.T. Pederson, B. Campbell, T. Moller, B. Nelson, S. Zorn, J. O'Connor, M.J. Attenburrow, A. Baird, J. Benjamin, S. Clare, P. Cowen, I.-.D. Huang, S. Hurley, H. Jones, F. Mada, A. Nevado-Holgado, A. Oladejo, E. Ribe, K. Smith, A. Vyas, Z. Hughes, R. Balice-Gordon, J. Duerr, J.R. Piro, J. Sporn, V.H. Perry, M. Cleal, G. Fryatt, D. Gomez-Nicola, R. Mancuso, R. Reynolds, N.A. Harrison, M. Cercignani, C.L. Clarke, E. Hoskins, C. Kohn, R. Murray, L. Wilcock, D. Wlazly, H. Mount. - In: ALZHEIMER'S & DEMENTIA. - ISSN 1552-5260. - 15:6(2019 Jun), pp. 776-787. [10.1016/j.jalz.2019.03.007]

Inflammatory biomarkers in Alzheimer's disease plasma

Morgan A. R.;Touchard S.;Leckey C.;O'Hagan C.;Nevado-Holgado A. J.;Barkhof F.;Bertram L.;Blin O.;Bos I.;Dobricic V.;Engelborghs S.;Frisoni G.;Frolich L.;Gabel S.;Johannsen P.;Kettunen P.;Kloszewska I.;Legido-Quigley C.;A. Lleo;Martinez-Lage P.;Mecocci P.;Meersmans K.;Molinuevo J. L.;Peyratout G.;Popp J.;Richardson J.;Sala I.;Scheltens P.;Streffer J.;Soininen H.;Tainta-Cuezva M.;Teunissen C.;Tsolaki M.;Vandenberghe R.;Visser P. J.;Vos S.;Wahlund L. -O.;Wallin A.;Westwood S.;Zetterberg H.;Lovestone S.;Morgan B. P.;Bullmore E. T.;Bhatti J.;Chamberlain S. J.;Correia M. M.;Crofts A. L.;Dickinson A.;Foster A. C.;Kitzbichler M. G.;Knight C.;Lynall M. -E.;C. Maurice;O'Donnell C.;Pointon L. J.;St George Hyslop P.;Turner L.;Vertes P.;Widmer B.;Williams G. B.;Leckey C. A.;Cavanagh J.;Deith C.;Farmer S.;McClean J.;McColl A.;McPherson A.;Scouller P.;Sutherland M.;Boddeke H. W. G. M.;Richardson J. C.;S. Khan;Murphy P.;Parker C. A.;Patel J.;D. Jones;de Boer P.;Kemp J.;Drevets W. C.;Nye J. S.;Wittenberg G.;Isaac J.;Bhattacharya A.;Carruthers N.;Kolb H.;Pariante C. M.;Turkheimer F.;Barker G. J.;Byrom H.;Cash D.;A. Cattaneo;Gee A.;Hastings C.;Mariani N.;McLaughlin A.;Mondelli V.;Nettis M.;Nikkheslat N.;Randall K.;Sheridan H.;Simmons C.;N. Singh;Van Loo V.;Vicente-Rodriguez M.;Wood T. C.;Worrell C.;Zajkowska Z.;Plath N.;Egebjerg J.;Eriksson H.;Gastambide F.;Adams K. H.;Jeggo R.;Thomsen C.;Pederson J. T.;Campbell B.;Moller T.;Nelson B.;Zorn S.;O'Connor J.;Attenburrow M. J.;Baird A.;Benjamin J.;Clare S.;Cowen P.;Huang I. -S. D.;Hurley S.;Jones H.;Mada F.;Nevado-Holgado A.;Oladejo A.;Ribe E.;Smith K.;Vyas A.;Hughes Z.;Balice-Gordon R.;Duerr J.;Piro J. R.;Sporn J.;Perry V. H.;Cleal M.;Fryatt G.;Gomez-Nicola D.;Mancuso R.;Reynolds R.;Harrison N. A.;Cercignani M.;Clarke C. L.;Hoskins E.;Kohn C.;Murray R.;Wilcock L.;Wlazly D.;Mount H.

2019

Abstract

Introduction: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a “Holy Grail” of AD research and intensively sought; however, there are no well-established plasma markers. Methods: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. Results: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). Discussion: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.

Scheda breve

Scheda completa

Scheda completa (DC)

	Parole chiave
	
			Alzheimer's disease; Biomarker; Complement; Inflammation; Plasma
		
	Settori scientifico-disciplinari dell'articolo
	
			Settore BIO/14 - Farmacologia
		
	Data di pubblicazione
	
			giu-2019
		
	Rivista in ANCE
	
			ALZHEIMER'S & DEMENTIA
		
	DOI
	
			https://dx.doi.org/10.1016/j.jalz.2019.03.007
		
	Tipologia
	
			Article (author)
		
	Appare nelle tipologie:
	
			01 - Articolo su periodico

File in questo prodotto:

File	Dimensione	Formato
j.jalz.2019.03.007.pdf accesso aperto Tipologia: Publisher's version/PDF Dimensione 530.53 kB Formato Adobe PDF Visualizza/Apri	530.53 kB	Adobe PDF	Visualizza/Apri

Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/706262

Citazioni

39

122

117

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca